----
Current ValuationThe current P/E ratio is -0.10, above the reasonable range, cheaper than 0.77% of the time in the past 1 years, and the industry ranks 95/605, the industry Median -1.87.
-0.103xP/E
$3.25Stock price
$-31.56Earnings per share
-0.103xP/E
Stock price$3.25Earnings per share$-31.56
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.31x
- Typical range
- -1.02x–-0.21x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
021426384
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -59.77x | 150.48% | $193.67B |
MRNAUSModerna | -27.62x | 15.45% | $87.04B |
CSLLYUSCSL Limited | -24.77x | -- | $63.89B |
NTRAUSNatera | -294.84x | 6.85% | $56.71B |
RVMDUSRevolution Medicines | -21.57x | 61.92% | $38.14B |
ROIVUSRoivant Sciences | -90.96x | 146.49% | $24.22B |
BNTXUSBioNTech SE | -11.27x | 19.07% | $22.03B |
INSMUSInsmed | -24.02x | 74.51% | $21.02B |
BBIOUSBridgebio Pharma | -18.76x | 28.67% | $12.98B |
SMMTUSSummit Therapeutics | -13.63x | 20.65% | $11.67B |
MDGLUSMadrigal Pharma | -31.96x | 51.32% | $10.39B |
PCVXUSVaxcyte | -9.41x | 48.18% | $10.01B |
IBRXUSImmunityBio | -9.80x | 151.32% | $9.73B |
TWSTUSTwist Bioscience | -63.92x | 28.71% | $8.74B |
KYMRUSKymera Therapeutics | -29.08x | 5.24% | $8.71B |
CYTKUSCytokinetics | -9.63x | 6.73% | $8.61B |
ARWRUSArrowHead Pharma | -24.68x | 35,923.70% | $7.90B |
ABVXUSAbivax SA | -16.52x | 22.49% | $7.68B |
IONSUSIonis Pharma | -12.63x | 50.43% | $7.14B |
SYREUSSpyre Therapeutics | -46.90x | 45.67% | $7.05B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
